Free Trial

Roche (ROSW: Aa2/AA): 2Q24 Results

HEALTHCARE
  • Earnings Beat
  • Group Sales up +9% in Q2 to CHF 15,449 (3.7% ahead of consensus)
  • Both Pharma and Diagnostics doing well.
  • Outlook raised with FY24 mid-single-digit increase now expected
  • Pipeline is strong.
  • Has issued in EUR & USD already this year.
  • No imminent need for finance.
  • WtAvg years of 7.76 could be longer though.

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.